

In SAH... After the Trauma

Nimotop for 21 Days... Neuroprotection to Improve Outcomes

Whether ruptured congenital aneurysm, or post traumatic subarachnoid hemorrhage, in clinical studies NIMOTOP as adjunct therapy has been shown to reduce the incidence and severity of neurological deficits.^{1,2}

Nimotop is an adjunct in the management of SAH. In view of its potential usefulness in improving neurologic outcomes in some patients, an early decision should be made regarding the use of the drug.

The most commonly reported adverse event with Nimotop was decreased blood pressure (5.0%). Please see the product monograph for important patient safety and monitoring information.

Pr ^(nimodipine)
Nimotop[®]
I.V. / Capsules

For 21 days. Improving outcomes

Bayer 

Healthcare Division

MEMBER
PAAB PMAC NM 92-0598E

Epilepsy is the last thing on these active minds... Tegretol CR at work!



Effective seizure control

- Significant clinical benefit with excellent control of epileptic seizures.^{1,2}

Impressive safety profile

- Stable carbamazepine plasma levels can lead to a lower minimal incidence of concentration - dependent side effects than regular Tegretol.⁴
- A high degree of tolerability.^{2*}

Achieve and maintain good seizure control with a low incidence of concentration - dependent side effects.⁴

One of the most commonly reported side effects with carbamazepine is drowsiness. This reaction usually occurs only during the initial phase of therapy⁴ and can be minimized by using controlled-release carbamazepine. (Pr Tegretol[®] CR).³

Carbamazepine is not effective in controlling absence, myoclonic or atonic seizures, and does not prevent the generalization of epileptic discharge. Moreover, exacerbation of seizures may occasionally occur in patients with atypical absences.⁴

*See Product Monograph for important warnings prior to prescribing.

Pr Tegretol[®] CR
(controlled release carbamazepine)
and
Pr Tegretol[®] Suspension
(carbamazepine)

HELPING EPILEPSY PATIENTS REACH THEIR FULL POTENTIAL


NOVARTIS

Novartis Pharmaceuticals Canada Inc.
Dorval, Québec H9R 4P5



TEG-98-03-4653E

Diurnal plasma concentration curves between regular Tegretol and Tegretol CR in children (n=25).³



Adapted from Eeg-Olofsson O. J Child Neurol 1990; 5: 159-165

Pr Tegretol[®] CR versus regular Pr Tegretol[®]

- Equivalent and/or improved efficacy and tolerability.⁶
- May significantly reduce seizure frequency.⁷
- Reduced interference with cognitive function.⁵